Tags

Type your tag names separated by a space and hit enter

New approaches to treatment of secondary hyperparathyroidism.
Curr Opin Investig Drugs. 2008 Apr; 9(4):363-70.CO

Abstract

A large number of patients with chronic kidney disease are affected by secondary hyperparathyroidism. The related mineral metabolism abnormalities are associated with an increased relative risk of morbidity and mortality. The management of secondary hyperparathyroidism is made more complex by the fact that the disease progresses over time. Recent approaches to its management include vitamin D analogs, non-calcium/non-aluminum containing phosphate binders and calcimimetics.

Authors+Show Affiliations

Department of Nephrology, Dialysis and Renal Transplantation, A Manzoni Hospital, Lecco, Italy. f.locatelli@ospedale.lecco.itNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

18393103

Citation

Locatelli, Francesco, et al. "New Approaches to Treatment of Secondary Hyperparathyroidism." Current Opinion in Investigational Drugs (London, England : 2000), vol. 9, no. 4, 2008, pp. 363-70.
Locatelli F, Limardo M, Pontoriero G. New approaches to treatment of secondary hyperparathyroidism. Curr Opin Investig Drugs. 2008;9(4):363-70.
Locatelli, F., Limardo, M., & Pontoriero, G. (2008). New approaches to treatment of secondary hyperparathyroidism. Current Opinion in Investigational Drugs (London, England : 2000), 9(4), 363-70.
Locatelli F, Limardo M, Pontoriero G. New Approaches to Treatment of Secondary Hyperparathyroidism. Curr Opin Investig Drugs. 2008;9(4):363-70. PubMed PMID: 18393103.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - New approaches to treatment of secondary hyperparathyroidism. AU - Locatelli,Francesco, AU - Limardo,Monica, AU - Pontoriero,Giuseppe, PY - 2008/4/9/pubmed PY - 2008/7/11/medline PY - 2008/4/9/entrez SP - 363 EP - 70 JF - Current opinion in investigational drugs (London, England : 2000) JO - Curr Opin Investig Drugs VL - 9 IS - 4 N2 - A large number of patients with chronic kidney disease are affected by secondary hyperparathyroidism. The related mineral metabolism abnormalities are associated with an increased relative risk of morbidity and mortality. The management of secondary hyperparathyroidism is made more complex by the fact that the disease progresses over time. Recent approaches to its management include vitamin D analogs, non-calcium/non-aluminum containing phosphate binders and calcimimetics. SN - 1472-4472 UR - https://www.unboundmedicine.com/medline/citation/18393103/New_approaches_to_treatment_of_secondary_hyperparathyroidism_ L2 - https://medlineplus.gov/kidneyfailure.html DB - PRIME DP - Unbound Medicine ER -